Literature DB >> 33486885

Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirements.

Loreta A Kondili1, Antonio Craxì2, Alessio Aghemo3.   

Abstract

The World Health Organization (WHO) targets for eliminating HCV by 2030 may be overambitious for many high-income countries. Recent analyses (ie, data from 2017 to 2019) show that only 11 countries are on track for meeting WHO's elimination targets. For a country to be truly on track, it is important that the majority of infected individuals be identified and treated. There is still a need for country and population-specific evaluations within the different HCV screening and treatment strategies available, in order to assess their cost-effectiveness and sustainability and support an evidence-based policy for HCV elimination. Any health policy model is affected by the diversity and quality of the available data and by gaps in data. Given the differences among countries, comparing progress based on fixed global targets will not necessarily be suitable in the same measure for each country. In a recent document, the European Collaborators of Polaris Observatory provide insight into the limitations of the current WHO targets. The absolute targets identified by each country in accordance with the measures set by WHO would be essential in reaching the HCV elimination. All analytic models to assess the progress towards HCV elimination are based on projections to 2030 not including the impact of the COVID-19 pandemic on hepatitis-related services. With specific regard to the achievement of WHO hepatitis elimination goals, all measures that will be put in place during and after COVID-19 pandemic could be transferred in increasing diagnosis and linkage to care of people with hepatitis.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  COVID-19; HCV elimination; HCV screening; WHO targets; disease burden; microelimination

Year:  2021        PMID: 33486885     DOI: 10.1111/liv.14796

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  7 in total

Review 1.  Prevention of hepatocellular carcinoma and monitoring of high-risk patients.

Authors:  Eda Kaya; Guillermo Daniel Mazzolini; Yusuf Yilmaz; Ali Canbay
Journal:  Hepatol Forum       Date:  2022-01-09

Review 2.  Can Telemedicine Optimize the HCV Care Cascade in People Who Use Drugs? Features of an Innovative Decentralization Model and Comparison with Other Micro-Elimination Strategies.

Authors:  Riccardo Nevola; Valerio Rosato; Vincenza Conturso; Pasquale Perillo; Teresa Le Pera; Ferdinando Del Vecchio; Davide Mastrocinque; Annalisa Pappalardo; Simona Imbriani; Augusto Delle Femine; Alessia Piacevole; Ernesto Claar
Journal:  Biology (Basel)       Date:  2022-05-24

3.  Elimination of Hepatitis C in Southern Italy: A Model of HCV Screening and Linkage to Care among Hospitalized Patients at Different Hospital Divisions.

Authors:  Valerio Rosato; Loreta A Kondili; Riccardo Nevola; Pasquale Perillo; Davide Mastrocinque; Alessio Aghemo; Ernesto Claar
Journal:  Viruses       Date:  2022-05-19       Impact factor: 5.818

4.  Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation.

Authors:  Andrea Marcellusi; Francesco Saverio Mennini; Murad Ruf; Claudio Galli; Alessio Aghemo; Maurizia R Brunetto; Sergio Babudieri; Antonio Craxi; Massimo Andreoni; Loreta A Kondili
Journal:  Liver Int       Date:  2021-10-08       Impact factor: 8.754

5.  Opportunistic co-screening for HCV and COVID-19-related services: A creative response with a need for thoughtful reflection.

Authors:  Loreta A Kondili; Lucia Craxì; Massimo Andreoni; Francesco S Mennini; Homie Razavi
Journal:  Liver Int       Date:  2022-05       Impact factor: 8.754

6.  Epidemiology of HCV and HBV in a High Endemic Area of Southern Italy: Opportunities from the COVID-19 Pandemic-Standardized National Screening or One Tailored to Local Epidemiology?

Authors:  Riccardo Nevola; Vincenzo Messina; Aldo Marrone; Nicola Coppola; Carolina Rescigno; Vincenzo Esposito; Vincenzo Sangiovanni; Ernesto Claar; Mariantonietta Pisaturo; Francesco Maria Fusco; Pietro Rosario; Antonio Izzi; Raffaella Pisapia; Valerio Rosato; Paolo Maggi; Luigi Elio Adinolfi
Journal:  Biology (Basel)       Date:  2022-04-16

Review 7.  Hepatitis C: Standard of Treatment and What to Do for Global Elimination.

Authors:  Lorenza Di Marco; Claudia La Mantia; Vito Di Marco
Journal:  Viruses       Date:  2022-02-28       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.